Congratulations to Dr. Chantelle Cappiciotti on being recognized for pioneering work in glycan research by the CRC Program. GlycoNet Investigator Dr. Chantelle Capicciotti, from Queen’s University, has been recognized as… Read More
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate and… Read More
VANCOUVER, BC – On November 15, 2024, Acuitas Therapeutics, Inc. received the Association of Fundraising Professionals (AFP) Greater Vancouver Chapter’s Giving Hearts Award: Outstanding Corporation. Acuitas was nominated by their… Read More
Researchers at the University of British Columbia (UBC), BC Cancer, Harvard Medical School and Memorial Sloan Kettering Cancer Center (MSK) have pinpointed what could be the early genetic origins of… Read More
DiffuSphere™ is designed to enable precise drug delivery at therapeutic dose levels directly into target tissues, enhancing efficacy while minimizing systemic drug levels to optimize safety In clinical trials, a… Read More
